Earnings Call · Q1 FY2023·2023-05-09

Q1 23EPS -19.70%·Rev n/aQ4 22EPS +10.59%·Rev n/aQ3 22EPS +12.90%·Rev n/aQ2 22EPS -14.13%·Rev n/a⚠ consensus missing

Esperion Therapeutics, Inc. ESPR

Tiffany Aldrich — Associate Director, Corporate Communications

Sheldon Koenig — Chief Executive Officer

Eric Warren — Chief Commercial Officer

Benjamin Halladay — Chief Financial Officer

+5.2%1d on move date+5.6% vs SPY3d+10.4%5d+25.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ESPR calls or request research access.

More ESPR calls Browse calls Request research access